文献速递睡眠呼吸障碍

乙酰唑胺治疗阻塞性与中枢性睡眠呼吸暂停:系统评价与荟萃分析

Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis.
PubMed 文献 · Chest · 2020-08-05

该系统评价与荟萃分析纳入28项研究(13项OSA/15项CSA,乙酰唑胺组542例,对照组553例),评估口服乙酰唑胺对成人睡眠呼吸暂停的疗效。结果显示,与对照相比,乙酰唑胺使呼吸暂停低通气指数(AHI)降低37.7%(95%CI -44.7至-31.3),相当于13.8次/小时(95%CI -16.3至-11.4),并改善氧饱和度最低值+4.4%(95%CI 2.3至6.5)。OSA与CSA疗效相似,高剂量(至少达500 mg/d)效果更显著。

要点

  • 乙酰唑胺短期治疗可降低OSA和CSA患者的AHI,并改善氧饱和度最低值。
  • OSA与CSA的AHI改善程度相似,高剂量(至少500 mg/d)效果更显著。
  • 证据质量中等(AHI)至极低(氧饱和度最低值),长期疗效待研究。

核心结论

  • 短期口服乙酰唑胺可改善成人OSA和CSA,表现为AHI降低和氧饱和度最低值提高。
  • 乙酰唑胺对OSA与CSA的疗效相似,且高剂量(至少500 mg/d)的AHI降低效果更显著。
  • 需要长期随访的严谨研究评估乙酰唑胺对睡眠呼吸暂停患者的慢性治疗价值。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE和ClinicalTrials.gov自建库至2019年3月11日。
  • 纳入任何设计、任何语言的成人OSA/CSA口服乙酰唑胺 vs 无乙酰唑胺(对照)并报告睡眠呼吸暂停相关结局的研究。
  • 共纳入28项研究(13项OSA/15项CSA;乙酰唑胺组542例,对照组553例),对24项结局进行荟萃分析。
  • 乙酰唑胺剂量范围36至1000 mg/d,治疗时长1至90天(中位6天)。
  • 证据质量采用GRADE方法评级。

主要发现

  • 乙酰唑胺 vs 对照降低AHI效应量为-0.7(95%CI -0.83至-0.58;I2=0%;中等证据质量),相当于降低37.7%(95%CI -44.7至-31.3)或13.8次/小时(95%CI -16.3至-11.4;对照组AHI=36.5次/小时)。
  • AHI降低在OSA与CSA间相似,但高剂量(至少达500 mg/d)时显著更大。
  • 乙酰唑胺改善氧饱和度最低值+4.4%(95%CI 2.3至6.5;I2=63%;无效应修饰证据;极低证据质量)。
  • 乙酰唑胺还改善若干次要结局,包括睡眠质量指标和血压(多为低证据质量)。

关键数值与推荐

  • 主要结局为呼吸暂停低通气指数(AHI)和氧饱和度最低值。
  • AHI降低效应量为-0.7(95%CI -0.83至-0.58),对应降低37.7%(95%CI -44.7至-31.3)或13.8次/小时(95%CI -16.3至-11.4)。
  • 氧饱和度最低值改善+4.4%(95%CI 2.3至6.5)。
  • 乙酰唑胺剂量范围36至1000 mg/d,高剂量(至少500 mg/d)效果更显著。

临床怎么用

  • 对于OSA或CSA成人患者,可考虑短期使用乙酰唑胺以降低AHI和改善氧饱和度最低值。
  • OSA与CSA患者均可从乙酰唑胺治疗中获益,无需仅限CSA。
  • 高剂量(至少500 mg/d)可能带来更显著的AHI降低,但需权衡不良反应。
  • 长期疗效尚未确定,慢性治疗决策需谨慎并个体化。

局限性

  • 纳入研究治疗时长多为短期(中位6天),长期疗效未知。
  • 氧饱和度最低值结局证据质量极低,异质性中等(I2=63%)。
  • 部分次要结局证据质量低。
  • 未报告长期随访的严谨研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapy options for OSA and central sleep apnea (CSA) are limited, thus many patients remain untreated. Clinically, acetazolamide is sometimes used for CSA; however, given overlapping pathophysiologic properties of OSA and CSA, we hypothesized that acetazolamide is equally effective for both types. Prior reviews focused on specific subtypes of sleep apnea, study designs, and languages, thus including few studies (typically ≤3) limiting insights. RESEARCH QUESTION: How efficacious is acetazolamide for sleep apnea, and is its effect modified by sleep apnea type or acetazolamide dose? STUDY DESIGN AND METHODS: We queried MEDLINE, EMBASE, and ClinicalTrials.gov from inception until March 11, 2019. Any study in which adults with OSA/CSA received oral acetazolamide vs no acetazolamide (control) that reported sleep apnea-related outcomes was eligible, independent of study design or language. Two reviewers independently assessed eligibility and abstracted data. Primary outcomes were apnea-hypopnea index (AHI) and oxygen saturation nadir. Quality of evidence (QoE) was rated with the use of Grades of Recommendation Assessment, Development and Evaluation methods. RESULTS: We included 28 studies (13 OSA/15 CSA; NSubjects,Acetazolamide = 542; NSubjects,Control = 553) that enabled meta-analyses for 24 outcomes. Acetazolamide doses ranged from 36 to 1000 mg/d and treatment duration from 1 to 90 d (median, 6 d). Overall, acetazolamide vs control lowered the AHI by -0.7 effect sizes (95% CI, -0.83 to -0.58; I2 = 0%; moderate QoE) that corresponded to a reduction of 37.7% (95% CI, -44.7 to -31.3) or 13.8/h (95% CI, -16.3 to -11.4; AHIControl = 36.5/h). The AHI reduction was similar in OSA vs CSA, but significantly greater with higher doses (at least up to 500 mg/d). Furthermore, acetazolamide improved oxygen saturation nadir by +4.4% (95% CI, 2.3 to 6.5; I2 = 63%; no evidence of effect modification; very low QoE) and several secondary outcomes that included sleep quality measures and BP (mostly low QoE). INTERPRETATION: Short-term acetazolamide improved both OSA and CSA. Rigorous studies with long-term follow up are warranted to assess Acetazolamide's value for the chronic treatment of patients with sleep apnea. CLINICAL TRIAL REGISTRATION: PROSPERO (CRD42019147504).

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Schmickl CN, Landry SA, Orr JE, et al. Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis. Chest. 2020. PMID: 32768459. doi:10.1016/j.chest.2020.06.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。